SeaCrest Wealth Management’s PDL BioPharma, Inc. PDLI Stock Holding History

SeaCrest Wealth Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,500	Closed	-$6K	–	2180
2019 Q1	$6K	Hold	1,500	–	–	﹤0.01%	1696
2018 Q4	$4K	Hold	1,500	–	–	﹤0.01%	1796
2018 Q3	$4K	Hold	1,500	–	–	﹤0.01%	1960
2018 Q2	$4K	Hold	1,500	–	–	﹤0.01%	1911
2018 Q1	$4K	Hold	1,500	–	–	﹤0.01%	1881
2017 Q4	$4K	Buy	+1,500	New	+$4.61K	﹤0.01%	1903

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SeaCrest Wealth Management's PDLI Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2019, closing a stake of 1,500 shares — an estimated $6K sold.

SeaCrest Wealth Management first reported a position in PDLI in Q4 2017 and held it in 6 quarters. The position peaked at $6K in Q1 2019. 148 funds tracked by Wall St. Rank hold PDLI as of Q2 2019.

SeaCrest Wealth Management reported no remaining PDL BioPharma, Inc. position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 1,500 PDL BioPharma, Inc. shares in Q2 2019, an estimated $6K.
SeaCrest Wealth Management first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's PDL BioPharma, Inc. position peaked at $6K in Q1 2019.
148 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.